Diuretic Testing to Predict Kidney Disease Progression
Tests a diuretic challenge in adults with chronic kidney disease to predict disease progression.
Plain-language title generated from the registry record
Registry title: Diuretic Testing in Chronic Kidney Disease
Key facts
- Where
- Rotterdam, NetherlandsSee the site
Where in Netherlands
- Erasmus MCRotterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Erasmus Medical Center
- Trial code
- NCT06841692
- Record updated
- 7 August 2025
- Original description
The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are:Read full original descriptionShow less
Diuretic Testing in Chronic Kidney Disease
The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are:
Does a worse result of a diuretic test predict the progression of chronic kidney disease?
If there is a comparison group: Researchers will compare the diuretic test in patients with chronic kidney disease to healthy participants to see if the results are different in a healthy kidney.
Participants will undergo diuretic testing. This involves the administration of bumetanide and hydrochlorothiazide with subsequent blood and urine collections.
Inclusion: CKD stage G3 (creatinine-based eGFR 30-59 mL/min/1.73m2) during the last outpatient visit; eGFR within the expected range for age (a decline of 1 ml/min/1.73 m2 per year starting from age 40 is considered the normal age-related decline in kidney function.
Exclusion: Kidney transplant recipient; Use of calcineurin-inhibitors; Current treatment with inhibitors of Organic anion transporters: probenecid, pravastatin, cimetidine, cephalosporins, acetazolamide [22]; Active drug- or alcohol abuse; Not being able to tolerate a 28-day washout of one of the drugs interfering with diuretic testing; Known intolerance or allergy to the diuretics; Current systemic chemotherapy for malignancy; Autosomal dominant polycystic or tubulointerstitial kidney disease causing CKD; Clinically relevant heart failure (New York Heart Association class III or IV); Therapy-resistant hypertension, defined as systolic blood pressure > 180mmHg at the inclusion visit; Active hepatitis during last outpatient visit; Hypokalemia or hyperkalemia (K+ < 3.0mmol/L or K+ > 5.5 mmol/L) at inclusion visit; Hypo- or hypernatremia (Na+ < 130 mmol/L or Na+ > 150mmol/L) at inclusion visit; Life expectancy < 12 months; Current immunosuppressive treatment for glomerulonephritis; Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team; Inherited tubulopathy as the cause of CKD; Liver cirrhosis in advanced stage (Child-Pugh B or C); Women who are pregnant, breastfeeding, or planning on becoming pregnant before the test day.